I. Thomas

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

J. Utikal, C. Berking, D. Schadendorf, 2016, European journal of cancer.

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

J. Utikal, C. Berking, D. Schadendorf, 2016, European journal of cancer.

Association between Immune-Related Adverse Events and Survival in 319 Stage IV Melanoma Patients Treated with PD-1-Based Immunotherapy: An Approach Based on Clinical Chemistry

C. Garbe, P. Martus, A. Forschner, 2021, Cancers.

Primary Resistance to PD-1-Based Immunotherapy—A Study in 319 Patients with Stage IV Melanoma

C. Garbe, A. Forschner, U. Leiter, 2020, Cancers.

An open-label, single-arm, phase II trial of buparlisib in patients with melanoma brain metastases not eligible for surgery or radiosurgery—the BUMPER study

C. Garbe, F. Meier, T. Sinnberg, 2020, Neuro-oncology advances.

787O Adjuvant immunotherapy with nivolumab (NIVO) versus observation in completely resected Merkel cell carcinoma (MCC): Disease-free survival (DFS) results from ADMEC-O, a randomized, open-label phase II trial

A. Hauschild, S. Haferkamp, D. Schadendorf, 2022, Annals of Oncology.

Features and Long-Term Outcomes of Stage IV Melanoma Patients Achieving Complete Response Under Anti-PD-1-Based Immunotherapy

A. Forschner, U. Leiter, T. Sinnberg, 2023, American Journal of Clinical Dermatology.

Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

J. Utikal, A. Hauschild, S. Haferkamp, 2023, The Lancet.